Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
128M
-
Number of holders
-
246
-
Total 13F shares, excl. options
-
132M
-
Shares change
-
+4.94M
-
Total reported value, excl. options
-
$2.28B
-
Value change
-
+$66.1M
-
Put/Call ratio
-
0.21
-
Number of buys
-
147
-
Number of sells
-
-116
-
Price
-
$17.31
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2025
322 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q2 2025.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 246 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 132M shares
.
Largest 10 shareholders include Avoro Capital Advisors LLC (12.2M shares), EcoR1 Capital, LLC (11.9M shares), VANGUARD GROUP INC (10.2M shares), MORGAN STANLEY (9.75M shares), WELLINGTON MANAGEMENT GROUP LLP (8.98M shares), Deep Track Capital, LP (7M shares), BlackRock, Inc. (6.4M shares), AQR CAPITAL MANAGEMENT LLC (5.98M shares), UBS Group AG (4.74M shares), and STATE STREET CORP (3.56M shares).
This table shows the top 246 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.